Ann: Quarterly Update and Appendix 4C, page-22

No mention of the need to fundraise - but it is clearly reported in the 4C.

IMO clearly just a matter of when not if for PCK... but am hesitant to buy more until cap raise and consequent dilution - could easily be another 12 months (or more) before profitability. FDA is also not a guarantee.

The good news is only 25% market penetration in Australian RAC and 5% in UK aged care. UK at 5% is $1M ARR and has 25% quarter on quarter growth. Painchek can be close to break even with UK RAC getting to 15% market penetration. Hospital, infant, children, home care and additional RAC across EU, ANZ and North America should be clear profit - and the foundations for these massive market segments is already in place...